Camille Samuels is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. Her investment interests span early-stage biotech to medical devices to consumer health. For instance, she serves on the board of directors of Unity biotech, a healthspan and longevity company.
Prior to Venrock, Cami spent over a decade as a Managing Director at Versant Ventures, a leading life sciences venture capital firm. While at Versant, Cami seeded Kythera (makers of Kybella) and served on the company’s board through its IPO and eventual sale to Allergan for $2.1B. In addition, she served as a board member or a board observer on many other innovative healthcare companies including Achaogen (AKAO), Carmenta (acquired by Progenity), Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acquired by Affymetrix) and Syrrx (acquired by Takeda).